share_log

424B5: Prospectus

424B5: Prospectus

424B5：募資說明書
美股SEC公告 ·  08/21 13:22
Moomoo AI 已提取核心訊息
SeaStar Medical Holding Corporation, a medical technology company, has entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, dated August 20, 2024. Under the agreement, SeaStar Medical may offer and sell up to $25 million of its common stock from time to time through Wainwright. The sales may be made on the Nasdaq Capital Market or other existing trading markets in the United States. Wainwright will act as a sales agent and will use commercially reasonable efforts to sell the shares on behalf of SeaStar Medical. The offering will terminate upon the termination of the agreement by either SeaStar Medical or Wainwright. This move comes after SeaStar Medical's recent developments, including the receipt of an approvable letter from the FDA for its Selective Cytopheretic Device (SCD) for pediatric use and the initiation of a pivotal trial for the SCD in adult patients with acute kidney injury. The company's common stock and warrants are traded on Nasdaq under the symbols 'ICU' and 'ICUCW,' respectively.
SeaStar Medical Holding Corporation, a medical technology company, has entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, dated August 20, 2024. Under the agreement, SeaStar Medical may offer and sell up to $25 million of its common stock from time to time through Wainwright. The sales may be made on the Nasdaq Capital Market or other existing trading markets in the United States. Wainwright will act as a sales agent and will use commercially reasonable efforts to sell the shares on behalf of SeaStar Medical. The offering will terminate upon the termination of the agreement by either SeaStar Medical or Wainwright. This move comes after SeaStar Medical's recent developments, including the receipt of an approvable letter from the FDA for its Selective Cytopheretic Device (SCD) for pediatric use and the initiation of a pivotal trial for the SCD in adult patients with acute kidney injury. The company's common stock and warrants are traded on Nasdaq under the symbols 'ICU' and 'ICUCW,' respectively.
SeaStar Medical Holding Corporation是一家醫療技術公司，已經於2024年8月20日與H.C. Wainwright & Co., LLC簽訂了一份市場交易協議。根據該協議，SeaStar Medical可以隨時通過Wainwright以最高2500萬美元的價格，不時地提供和出售其普通股。銷售可以在納斯達克資本市場或美國的其他現有交易市場上進行。Wainwright將充當銷售代理人，並且將採取商業上合理的努力代表SeaStar Medical出售股票。該交易將在SeaStar Medical或Wainwright任一方終止協議時終止。這一舉措是SeaStar Medical最近的發展之一，包括獲得FDA對其兒科用選擇性細胞修復裝置（SCD）的可批准信函，並啓動成人急性腎損傷患者SCD的關鍵試驗。該公司的普通股和權證在納斯達克交易，代碼分別爲'ICU'和'ICUCW'。
SeaStar Medical Holding Corporation是一家醫療技術公司，已經於2024年8月20日與H.C. Wainwright & Co., LLC簽訂了一份市場交易協議。根據該協議，SeaStar Medical可以隨時通過Wainwright以最高2500萬美元的價格，不時地提供和出售其普通股。銷售可以在納斯達克資本市場或美國的其他現有交易市場上進行。Wainwright將充當銷售代理人，並且將採取商業上合理的努力代表SeaStar Medical出售股票。該交易將在SeaStar Medical或Wainwright任一方終止協議時終止。這一舉措是SeaStar Medical最近的發展之一，包括獲得FDA對其兒科用選擇性細胞修復裝置（SCD）的可批准信函，並啓動成人急性腎損傷患者SCD的關鍵試驗。該公司的普通股和權證在納斯達克交易，代碼分別爲'ICU'和'ICUCW'。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息